These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20834039)

  • 1. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
    Comi G; Abramsky O; Arbizu T; Boyko A; Gold R; Havrdová E; Komoly S; Selmaj K; Sharrack B; Filippi M;
    Mult Scler; 2010 Nov; 16(11):1360-6. PubMed ID: 20834039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
    Comi G; Pulizzi A; Rovaris M; Abramsky O; Arbizu T; Boiko A; Gold R; Havrdova E; Komoly S; Selmaj K; Sharrack B; Filippi M;
    Lancet; 2008 Jun; 371(9630):2085-92. PubMed ID: 18572078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
    Polman C; Barkhof F; Sandberg-Wollheim M; Linde A; Nordle O; Nederman T;
    Neurology; 2005 Mar; 64(6):987-91. PubMed ID: 15781813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo-controlled trial of oral laquinimod for multiple sclerosis.
    Comi G; Jeffery D; Kappos L; Montalban X; Boyko A; Rocca MA; Filippi M;
    N Engl J Med; 2012 Mar; 366(11):1000-9. PubMed ID: 22417253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral laquinimod therapy in relapsing multiple sclerosis.
    Preiningerova J
    Expert Opin Investig Drugs; 2009 Jul; 18(7):985-9. PubMed ID: 19527103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G; Filippi M; Wolinsky JS
    Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.
    Ziemssen T; Tumani H; Sehr T; Thomas K; Paul F; Richter N; Samara E; Spiegelstein O; Sorani E; Bar-Ilan O; Mimrod D; Hayardeny L
    J Neuroinflammation; 2017 Aug; 14(1):172. PubMed ID: 28859672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
    Gold R; Kappos L; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Tornatore C; Sweetser MT; Yang M; Sheikh SI; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1098-107. PubMed ID: 22992073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
    O'Connor PW; Li D; Freedman MS; Bar-Or A; Rice GP; Confavreux C; Paty DW; Stewart JA; Scheyer R; ;
    Neurology; 2006 Mar; 66(6):894-900. PubMed ID: 16567708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral laquinimod treatment in multiple sclerosis.
    Fernández O
    Neurologia; 2011 Mar; 26(2):111-7. PubMed ID: 21163185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laquinimod in the treatment of relapsing remitting multiple sclerosis.
    Hainke U; Thomas K; Ziemssen T
    Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):701-9. PubMed ID: 27089834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
    Comi G; Dadon Y; Sasson N; Steinerman JR; Knappertz V; Vollmer TL; Boyko A; Vermersch P; Ziemssen T; Montalban X; Lublin FD; Rocca MA; Volkinshtein R; Rubinchick S; Halevy N; Filippi M
    Mult Scler; 2022 Apr; 28(4):608-619. PubMed ID: 34378456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
    Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
    Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.
    Constantinescu SE; Constantinescu CS
    Expert Rev Clin Pharmacol; 2016; 9(1):49-57. PubMed ID: 26536299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.
    Curtin F; Porchet H; Glanzman R; Schneble HM; Vidal V; Audoli-Inthavong ML; Lambert E; Hartung HP
    Mult Scler Relat Disord; 2016 Sep; 9():95-100. PubMed ID: 27645352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.